Multi-parametric MRI (mpMRI) has demonstrated a significant opportunity to improve the detection and diagnosis of clinically significant prostate cancer and reduce the typical upgrading seen in the past at radical prostatectomy.
Researchers have shown that the number of cores needed to diagnose a clinically significant cancer is threefold less in the in-bore MR guided biopsy than the fusion biopsy because in-bore MRI-guided biopsy can place needle right in the lesion, hence higher inclusion of cancerous tissue.
In-bore MRI-based diagnosis and treatment of prostate cancer directly uses power of mpMRI. Experts report that in-bore approach is cost-effective than other image-guided approach inclusion MRI fusion biopsy using ultrasound.
Transperineal approach has a higher detection rate of cancer in an anterior lesion than trans-rectal approach.
Focal ablative therapy of prostate cancer is a viable option for prostate cancer management particularly among men undergoing active surveillance.
Novel MR images can identify focal habitats within the gland and focal lesions, representing intratumoral heterogeneity. A precision guidance device may separately sample these sub-lesions, it will enable targeted diagnosis and therapy of prostate cancer.